Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794868 | Ophthalmology Retina | 2017 | 10 Pages |
Abstract
Vision gains achieved with anti-vascular endothelial growth factor therapy in VIEW 1 were largely maintained by continued treatment with IAI 2 mg in the extension study. Anti-vascular endothelial growth factor injections (including 4 years of IAI 2 mg) were well-tolerated with no new safety signals compared with the known profile of IAI.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter K. MD, Michael MD, Michael MD, Robert MD, Kristine OD, PhD, Namrata OD, Alyson J. MD, PhD, Karen W. MS, Xiaoping PhD, Zinaria MD, W. Lloyd MD,